Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GTHX | Common Stock | Options Exercise | $3.9K | +10K | +24.39% | $0.39* | 51K | May 11, 2021 | Direct | |
transaction | GTHX | Common Stock | Sale | -$191K | -10K | -19.61% | $19.10* | 41K | May 11, 2021 | Direct | F1, F2 |
transaction | GTHX | Common Stock | Options Exercise | $3.9K | +10K | +24.39% | $0.39* | 51K | May 12, 2021 | Direct | |
transaction | GTHX | Common Stock | Sale | -$201K | -10K | -19.61% | $20.07* | 41K | May 12, 2021 | Direct | F1, F3 |
transaction | GTHX | Common Stock | Options Exercise | $3.9K | +10K | +24.39% | $0.39* | 51K | May 13, 2021 | Direct | |
transaction | GTHX | Common Stock | Sale | -$205K | -10K | -19.61% | $20.54* | 41K | May 13, 2021 | Direct | F1, F4 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GTHX | Stock Options (Right to Buy) | Options Exercise | $0 | -10K | -2.96% | $0.00 | 327K | May 11, 2021 | Common Stock | 10K | $0.39 | Direct | F5 |
transaction | GTHX | Stock Options (Right to Buy) | Options Exercise | $0 | -10K | -3.06% | $0.00 | 317K | May 12, 2021 | Common Stock | 10K | $0.39 | Direct | F5 |
transaction | GTHX | Stock Options (Right to Buy) | Options Exercise | $0 | -10K | -3.15% | $0.00 | 307K | May 13, 2021 | Common Stock | 10K | $0.39 | Direct | F5 |
Id | Content |
---|---|
F1 | This sale was effected pursuant to a Rule 10b5-1 trading plan. |
F2 | The price represents the weighted average price with a low of $18.69 and a high of $19.47. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4. |
F3 | The price represents the weighted average price with a low of $19.80 and a high of $20.28. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 3 to this Form 4. |
F4 | The price represents the weighted average price with a low of $20.42 and a high of $20.895. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 4 to this Form 4. |
F5 | All shares underlying this option have vested. |